90381 CPT® code: payer coverage and prior authorization90381 appears in 7 coverage policies from Aetna, Blue Cross & Blue Shield of Rhode Island, Capital Blue Cross, Centene.
| Payer | Policy | Role in policy | Reviewed | Document |
|---|---|---|---|---|
| Aetna | Clesrovimab-cfor (Enflonsia) (1088) | listed, no stance | Oct 9, 2026 | payer document |
| Aetna | Injectable Medications (0020) | listed, no stance (range 90281-90399) | Mar 5, 2026 | payer document |
| Aetna | Nirsevimab-alip (Beyfortus) (1038) | covered if criteria are met | Oct 9, 2026 | payer document |
| Aetna | Palivizumab (Synagis) (0318) | listed, no stance | Aug 21, 2026 | payer document |
| Blue Cross & Blue Shield of Rhode Island | Immunizations Adult and Pediatric MEDICAL COVERAGE POLICY | 4 | covered if criteria are met | Jun 9, 2026 | payer document |
| Capital Blue Cross | Experimental and Investigational Procedures (MP 4.002) Procedure codes: Vaccines | listed, no stance | Sep 1, 2026 | payer document |
| Centene | Nirsevimab-alip (Beyfortus) (CP.PHAR.614) | covered if criteria are met | Aug 1, 2026 | payer document |
From payers' published prior-auth lists, coverage policies and state Medicaid fee schedules, updated Oct 16, 2026. The role is what the policy's own code table or text says about the code. Not a guarantee of coverage or payment; verify with the payer. CPT® is a registered trademark of the American Medical Association.